Search results
Results from the WOW.Com Content Network
(Reuters) -Mayne Pharma has filed a lawsuit against India's Sun Pharma over infringements of patents related to a certain product used for menopause-related vaginal pain, the Australian drugmaker ...
Sun Pharmaceutical Industries Ltd. was established by Dilip Shanghvi in 1983 in Calcutta, West Bengal with five psychiatry products and a two-person marketing team. Today it is ranked number one in share of prescriptions with 12 classes of doctors in India and a market leader in Psychiatry, Neurology, Cardiology, Orthopaedics, Gastroenterology, Nephrology, Diabetology, Dermatology, Urology ...
This is an accepted version of this page This is the latest accepted revision, reviewed on 15 November 2024. Indian Businessman Dilip Shanghvi Born (1955-10-01) 1 October 1955 (age 69) Amreli, Gujarat, India Alma mater Bhawanipur Education Society College, University of Calcutta Occupation(s) Founder and MD of Sun Pharmaceuticals Spouse Vibha Shanghvi Children 2 Dilip Shanghvi (born 1 October ...
Zydus Lifesciences and Sun Pharmaceuticals have entered an agreement in October 2023 to co-market Desidustat. Sun Pharma will sell the drug as Rytstat , while Zydus will continue to sell it as Oxemia . [ 17 ]
AOL latest headlines, entertainment, sports, articles for business, health and world news.
Sun Pharma and Taro Announce Termination of Proposed Transaction HAWTHORNE, N.Y. & MUMBAI, India--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYS: TARO) ("Taro") and Sun Pharmaceutical ...
In 2008, Japanese pharmaceutical company Daiichi Sankyo acquired a controlling share in Ranbaxy [2] and in 2014, Sun Pharma acquired 100% of Ranbaxy in an all-stock deal. The Sun Pharma acquisition brought all new management to Ranbaxy, which had been laden with controversy (see Controversies below). Sun is the world's fifth largest specialty ...
Indian contract drug manufacturer Suven Pharmaceuticals said on Thursday it will merge with Cohance Lifesciences in an all-share deal, as it looks to further scale up its contract and development ...